Private Equity

Managers

Therapists' digital network SonderMind garners $2.5 mln

SonderMind Inc, a digital network of therapists, has secured $2.5 million in funding. Kickstart Seed Fund led the round with participation from Purple Arch Ventures, SpringTime Ventures, Service Provider Capital and Lanoha Ventures.

3 min read · 30 May 2018

Enterprise IPOs on a roll with Adaptive Insights on deck

3 min read · 30 May 2018

Angel rounds and valuations grew last year

1 min read · 29 May 2018

U.S. leads venture-fund returns: report

2 min read · 29 May 2018

XSeed Capital to raise $100 mln venture fund

XSeed Capital has set out to raise a $100 million venture capital fund, according to a filing with the SEC.

1 min read · 29 May 2018

Sequoia Capital files with SEC to raise its mammoth global growth fund

Sequoia Capital has filed with the SEC to raise its mammoth global growth fund, though it did not provide an update on its progress, according to a document submitted to the agency.

1 min read · 29 May 2018

MTech Capital targets $150 mln for venture fund

MTech Capital is targeting $150 million for a venture fund, according to a regulatory filing.

1 min read · 29 May 2018

Caffeinated Capital rakes in $75 mln for third fund

Caffeinated Capital has raised $75 million for its third fund, according to an SEC filing. San Francisco-based Caffeinated Capital is an early-stage venture firm.

1 min read · 29 May 2018

Myriad Genetics to buy VC-backed Counsyl for $375 mln

Myriad Genetics has agreed to acquire South San Francisco-based Counsyl, a provider of DNA screening, for $375 million. Lazard is providing financial advice to Myriad Genetics on the deal with Mintz Levin Cohn Ferris Glovsky and Popeo PC acting as legal counsel. And, Piper Jaffray is providing financial advice to Counsyl while Cooley LLP is serving as legal counsel. Counsyl's backers include Goldman Sachs, Founders Fund, Pilot Growth Equity and Felicis Ventures.

6 min read · 29 May 2018

Lion TCR attracts $20 mln Series A

Singapore-based Lion TCR, a developer of engineered T-cell immunotherapy against viral-related cancer and chronic hepatitis B, has secured $20 million in Series A funding. The investors in this round included Yashang Capital and Westlake Ventures Capital.

1 min read · 29 May 2018

Showing 3,851 to 3,860 of 19,970 results
1…385387…1000